<DOC>
	<DOC>NCT01803321</DOC>
	<brief_summary>This study is a pilot, ascending dose, multi-center, randomized, double blind, placebo controlled, pediatric study conducted in three phases.</brief_summary>
	<brief_title>Study to Evaluate the Safety and Tolerability of Two Doses of Rilonacept in Pediatric Subjects With Active Systemic Juvenile Idiopathic Arthritis (SJIA)</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Juvenile</mesh_term>
	<criteria>Inclusion Criteria include, but are not limited to, the following: Patients aged 4 to less than 21 years who meet the criteria for active SJIA Must have been on a stable dose of nonsteroidal antiinflammatory drugs (NSAIDs) for at least 4 weeks prior to the screening visit Exclusion Criteria include, but are not limited to, the following: Use of certain medications prior to the baseline visit History of recurrent infections</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>SJIA</keyword>
</DOC>